Source comparison
CJC-1295/Ipamorelin vs Tesamorelin/Ipamorelin: Research Application Comparison
Mechanism GHRH receptor agonist (extended half-life) + ghrelin receptor agonist GHRH analog (short half-life) + ghrelin receptor agonist CJC provides sustained stimulation; Tesamorelin offers daily pulse control Half-Life CJC: 6–8 days; Ipamorelin: ~2 hours Te
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist (extended half-life) + ghrelin receptor agonist
- GHRH analog (short half-life) + ghrelin receptor agonist
- CJC provides sustained stimulation; Tesamorelin offers daily pulse control
- Half-Life
- CJC: 6–8 days; Ipamorelin: ~2 hours
- Tesamorelin: 26–38 minutes; Ipamorelin: ~2 hours
- CJC's extended half-life reduces dosing frequency but limits temporal precision
- Dosing Frequency
- 1–2 times weekly
- Daily (once per day)
- CJC blend requires fewer administrations; Tesamorelin requires daily compliance
- Primary Effect
- Systemic GH elevation with broad anabolic effects
- Targeted visceral adipose tissue reduction
- CJC optimizes whole-body composition; Tesamorelin selectively mobilizes truncal fat
- Clinical Evidence
- Phase 1/2 trials in healthy adults and GH deficiency
- FDA-approved for HIV lipodystrophy with Phase 3 VAT reduction data
- Tesamorelin has stronger regulatory validation for specific visceral fat indication
- Body Composition Outcome
- Increased lean mass, reduced total body fat, improved skin/connective tissue
- 15.2% VAT reduction, preserved subcutaneous fat, improved metabolic markers
- Choose CJC for systemic recomposition; Tesamorelin for visceral fat-specific goals
- Side Effect Profile
- Injection site reactions, transient water retention, rare insulin resistance
- Injection site reactions, hyperglycemia risk in diabetic populations, arthralgia
- Both well-tolerated at standard doses; monitor glucose in metabolic disease models
- Research Application
- Protocols measuring lean mass gains, recovery, systemic GH optimization
- Protocols targeting visceral adiposity, metabolic syndrome, lipodystrophy models
- CJC suits performance and aging research; Tesamorelin suits metabolic disease studies